tetano
Editor, Senior Moderator
J Med Virol
. 2023 Dec;95(12):e29252.
doi: 10.1002/jmv.29252. A potential broad-spectrum neutralizing antibody against Betacoronavirus
Rong Wang[SUP] 1 [/SUP], Jiazheng Guo[SUP] 1 [/SUP], Jiansheng Lu[SUP] 1 [/SUP], Peng Du[SUP] 1 [/SUP], Jun Zhang[SUP] 1 [/SUP], YunZhou Yu[SUP] 1 [/SUP], Lei Chen[SUP] 1 [/SUP], Zhiqi Xiong[SUP] 2 [/SUP], Yuning Xiang[SUP] 2 [/SUP], Xiaodan Ni[SUP] 2 [/SUP], Junjie Xu[SUP] 1 [/SUP], Zhixin Yang[SUP] 1 [/SUP]
Affiliations
Three pandemics caused by human Betacoronavirus had broken out in the past two decades. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was one of the novel epidemic strains which caused the third pandemic, coronavirus disease 2019 (COVID-19), a global public health crisis. So far, more than millions of people have been infected. Considering the public health and economic impact of Betacoronavirus pandemic, drugs with broad-spectrum activity against these coronaviruses are urgently needed. In this study, two monoclonal antibodies targeting SARS-CoV-2 spike protein receptor-binding domain (RBD) with good neutralizing activity were used to construct a novel immunoglobulin-like bispecific antibody BI31. The neutralizing effect of BI31 against the pseudovirus and the authentic virus is better than that of its parent antibodies alone and in combination. What surprised us most was that the newly constructed bispecific antibody also had the neutralizing activity against SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) that the parent antibodies did not have. These suggested that the BI31 can not only be developed as a therapeutic drug against COVID-19 but it could also become a broad-spectrum therapeutic antibody against Betacoronavirus.
Keywords: Betacoronavirus; SARS-CoV-2; antibody neutralization; bispecific antibody; broad-spectrum antibody.
. 2023 Dec;95(12):e29252.
doi: 10.1002/jmv.29252. A potential broad-spectrum neutralizing antibody against Betacoronavirus
Rong Wang[SUP] 1 [/SUP], Jiazheng Guo[SUP] 1 [/SUP], Jiansheng Lu[SUP] 1 [/SUP], Peng Du[SUP] 1 [/SUP], Jun Zhang[SUP] 1 [/SUP], YunZhou Yu[SUP] 1 [/SUP], Lei Chen[SUP] 1 [/SUP], Zhiqi Xiong[SUP] 2 [/SUP], Yuning Xiang[SUP] 2 [/SUP], Xiaodan Ni[SUP] 2 [/SUP], Junjie Xu[SUP] 1 [/SUP], Zhixin Yang[SUP] 1 [/SUP]
Affiliations
- PMID: 38078658
- DOI: 10.1002/jmv.29252
Three pandemics caused by human Betacoronavirus had broken out in the past two decades. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was one of the novel epidemic strains which caused the third pandemic, coronavirus disease 2019 (COVID-19), a global public health crisis. So far, more than millions of people have been infected. Considering the public health and economic impact of Betacoronavirus pandemic, drugs with broad-spectrum activity against these coronaviruses are urgently needed. In this study, two monoclonal antibodies targeting SARS-CoV-2 spike protein receptor-binding domain (RBD) with good neutralizing activity were used to construct a novel immunoglobulin-like bispecific antibody BI31. The neutralizing effect of BI31 against the pseudovirus and the authentic virus is better than that of its parent antibodies alone and in combination. What surprised us most was that the newly constructed bispecific antibody also had the neutralizing activity against SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) that the parent antibodies did not have. These suggested that the BI31 can not only be developed as a therapeutic drug against COVID-19 but it could also become a broad-spectrum therapeutic antibody against Betacoronavirus.
Keywords: Betacoronavirus; SARS-CoV-2; antibody neutralization; bispecific antibody; broad-spectrum antibody.